Clinical trials: House Dust Mite Allergy
Allergic Rhinitis, Allergic Rhinoconjunctivitis
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
The purpose of this study is to assess the effect on various biomarkers of treatment with MK-8237 in participants with allergic rhinitis or rhinoconjunctivitis.
- Trial name
- NCT01852825
- Testing
- MK-8237, NAC
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Rhinitis
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis
The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared to placebo, for reduction of allergic…
- Trial name
- NCT00674700
- Testing
- 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Volunteers
- 509 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis
Efficacy and Safety Trial of Pangramin SLIT HDM-mix in Subjects With House Dust Mite Induced Rhinitis
Primary aim is to evaluate the efficacy of specific immunotherapy with Pangramin SLIT HDM-mix compared to placebo in the treatment of House Dust Mite (HDM) induced rhinitis with or without asthma.
- Trial name
- NCT01603056
- Testing
- Pangramin SLIT HDM mix.
- Where
- China
- Volunteers
- 617 people
- Sponsor
- ALK-Abelló A/S
Asthma, COPD
The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma.
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
- Trial name
- NCT03858686
- Testing
- FP-025 capsules
- Where
- 2 sites in Netherlands
- Volunteers
- 27 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus
Mite Asthma Pediatric Immunotherapy Trial
The trial aims to demonstrate efficacy of the House Dust Mite SLIT-tablet versus placebo as add-on treatment in children and adolescents (5-17 years) with House Dust Mite allergic asthma based on clinically relevant asthma…
- Conditions
- Allergic Asthma Due to Dermatophagoides Farinae, Allergic Asthma Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MAPIT (NCT03654976)
- Testing
- HDM SLIT-tablet
- Where
- 64 sites in United States, Bulgaria and 7 more
- Volunteers
- 533 people
- Sponsor
- ALK-Abelló A/S
Asthma
Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances.
- Trial name
- NCT00200850
- Testing
- House Dust Mite SLIT, High dose SLIT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Wisconsin, Madison
Allergic Rhinoconjunctivitis
Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study was to assess safety and tolerability of 3 different…
- Trial name
- NCT01489020
- Testing
- subcutaneous immunotherapy with DPT extract
- Where
- 2 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Roxall Medicina España S.A
Rhinoconjunctivitis
Phase II HDM-SPIRE Safety and Efficacy Study
The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep…
- Trial name
- NCT02150343
- Testing
- HDM-SPIRE
- Where
- 98 sites in United States, Canada and 6 more
- Volunteers
- 715 people
- Sponsor
- Circassia Limited
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)
The purpose of this study is to evaluate the dose-related effectiveness, the safety and the tolerability of MK-8237, compared to placebo, in the treatment of house dust mite (HDM)-induced allergic rhinitis/rhinoconjunctivitis in…
- Trial name
- NCT01644617
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 124 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.
- Trial name
- NCT01700192
- Testing
- MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets
- Volunteers
- 1,482 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to House Dust Mite
Efficacy and Safety of 100IR, 300IR, 500IR Sublingual House Dust Mite Tablets in Allergic Rhinitis Environment Exposure Chamber Model
The purpose of this study is to assess the effect of 3 doses of sublingual house dust mite (HDM) tablets versus placebo in the change from baseline of rhinitis total symptom score during the allergen chamber challenge before and…
- Trial name
- NCT01527188
- Testing
- 100 IR house dust mites allergen extract tablet, 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Where
- Canada
- Volunteers
- 355 people
- Sponsor
- Stallergenes Greer
Dermatitis, Atopic
Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)
The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24 months old children.
- Trial name
- NCT00152464
- Testing
- Levocetirizine
- Volunteers
- 514 people
- Sponsor
- UCB Pharma SA
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Adolescent Mite Allergy Safety Evaluation
This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.
- Trial name
- AMASE (NCT04541004)
- Testing
- HDM SLIT-tablet
- Where
- 27 sites in Czechia, Germany and 1 more
- Volunteers
- 253 people
- Sponsor
- ALK-Abelló A/S
Asthma
Screening Inhaled Allergen Challenge for Dermatophagoides Farinae
This study is designed to identify Dermatophagoides farinae, or Der f, sensitive asthmatics who demonstrate a late phase asthmatic response after Der f inhalation.
- Trial name
- MiteScreen (NCT03049111)
- Testing
- Der f
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of North Carolina, Chapel Hill
Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
House Dust Mite Allergy Trial In Children
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
- Conditions
- Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MATIC (NCT04145219)
- Testing
- Sublingual allergy immunotherapy tablet
- Where
- 113 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,460 people
- Sponsor
- ALK-Abelló A/S
Perennial Allergic Rhinitis, Rhinitis, Allergic
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explored the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers.
- Trial name
- NCT05122143
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Altamira Medica Ltd.
Venous Thromboembolism, Atopic Dermatitis
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
- Conditions
- Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT04969653
- Testing
- Exposure of venous thromboembolism
- Where
- United Kingdom
- Volunteers
- 754,745 people
- Sponsor
- Momentum Data
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
- Trial name
- NCT02443805
- Testing
- 300 IR
- Where
- 2 sites in United States, France
- Volunteers
- 1,607 people
- Sponsor
- Stallergenes Greer
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)
The purpose of this study is to evaluate the safety of two doses (6 Development Units [DU] and 12 DU) of MK-8237 sublingual tablets compared to Placebo in adolescents with house dust mite-induced allergic…
- Trial name
- NCT01678807
- Testing
- MK-8237 6 DU, MK-8237 12 DU
- Volunteers
- 195 people
- Sponsor
- ALK-Abelló A/S
Allergy, Asthma
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
To demonstrate superiority of ALK HDM tablets versus placebo in immune response, measured as change of D.farinae specific immunoglobulin G4 (IgG4) from baseline to end of treatment with ALK HDM tablets given once daily over 60…
- Conditions
- Allergy, Asthma, Rhinitis
- Trial name
- NCT02596321
- Testing
- Mitizax
- Where
- 9 sites in Belarus, Russia
- Volunteers
- 112 people
- Sponsor
- Abbott